AtLAS-A Trial
Phase 4
60
about 5.7 years
12–17
1 site in OH
Why this study is shown
What this study is about
This trial is testing whether duloxetine or escitalopram are effective in treating anxiety and depression in adolescents. It involves a double-blind treatment period followed by an open-label, naturalistic follow-up phase lasting 2069 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Duloxetine
- 2.Take Escitalopram
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
duloxetine (SNRI; increases serotonin and norepinephrine levels), escitalopram (SSRI; increases serotonin availability)
oral (Delayed Release Oral Capsule), oral (Oral Tablet)
Primary: Change from Baseline in Pediatric Anxiety Rating Scale (PARS) severity score, Change from Baseline in the Clinical Global Impression of Severity (CGI-S)
Psychiatry / Mental Health